COMET Initiative | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Contributors

Dohner, H. Estey, E. Grimwade, D. Amadori, S. Appelbaum, F. R. Buchner, T. Dombret, H. Ebert, B. L. Fenaux, P. Larson, R. A. Levine, R. L. Lo-Coco, F. Naoe, T. Niederwieser, D. Ossenkoppele, G. J. Sanz, M. Sierra, J. Tallman, M. S. Tien, H. F. Wei, A. H. Lowenberg, B. Bloomfield, C. D.

Publication

Journal: Blood
Volume: 129
Issue: 4
Pages: 424 - 447
Year: 2017
DOI: 10.1182/blood-2016-08-733196

Further Study Information

Current Stage: Not Applicable
Date:
Funding source(s): H.D¨ohner was supported by SFB 1074 “Experimental models and clinical translation in leukemia” funded by the Deutsche Forschungsgemeinschaft (DFG). D.G. was grateful for support from the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (grant reference RP-PG-0108-10093). J.S. was supported by grants from the Ag`encia de Gesti´o d’Ajuts Universitaris i de Recerca (AGAUR) 2014SGR-1281, Instituto de Salud Carlos III (ISCIII) RD12/0036/0071 and Fondo de Investigaci´on en Salud (FIS) PI14/00450. F.L.-C. was supported by Associazione Italiana per la Ricerca sul Cancro grant AIRC I.G. 5916. C.D.B. was supported by National Institutes of Health National Cancer Institute grants CA180861, CA016058.

Health Area

Disease Category: Cancer

Disease Name: Leukemia (acute myeloid)

Target Population

Age Range: 18 - 100

Sex: Either

Nature of Intervention: Drug

Stakeholders Involved

- Clinical experts
- Researchers

Study Type

- COS for clinical trials or clinical research

Method(s)

- Literature review
- Semi structured discussion

The panel included 22 international members with recognized clinical and research expertise in AML. The panel met 3 times. Literature searches, categorization of evidence, and arrival at consensus were done.